Viridian Therapeutics, Inc. (VRDN)
22.43
+1.63
(+7.84%)
USD |
NASDAQ |
Oct 20, 16:00
22.49
+0.06
(+0.27%)
After-Hours: 20:00
Viridian Therapeutics Research and Development Expense (TTM) : 324.21M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 324.21M |
| March 31, 2026 | 339.26M |
| December 31, 2025 | 338.47M |
| September 30, 2025 | 321.22M |
| June 30, 2025 | 304.10M |
| March 31, 2025 | 273.53M |
| December 31, 2024 | 237.61M |
| September 30, 2024 | 204.19M |
| June 30, 2024 | 165.41M |
| March 31, 2024 | 149.41M |
| December 31, 2023 | 159.24M |
| September 30, 2023 | 160.06M |
| June 30, 2023 | 151.93M |
| March 31, 2023 | 133.63M |
| December 31, 2022 | 100.70M |
| September 30, 2022 | 83.84M |
| June 30, 2022 | 69.81M |
| March 31, 2022 | 60.70M |
| December 31, 2021 | 56.77M |
| September 30, 2021 | 49.60M |
| June 30, 2021 | 44.42M |
| March 31, 2021 | 35.53M |
| December 31, 2020 | 27.71M |
| September 30, 2020 | 20.86M |
| June 30, 2020 | 26.91M |
| Date | Value |
|---|---|
| March 31, 2020 | 31.79M |
| December 31, 2019 | 34.58M |
| September 30, 2019 | 34.47M |
| June 30, 2019 | 32.91M |
| March 31, 2019 | 32.76M |
| December 31, 2018 | 30.42M |
| September 30, 2018 | 27.18M |
| June 30, 2018 | 24.80M |
| March 31, 2018 | 21.92M |
| December 31, 2017 | 19.62M |
| September 30, 2017 | 18.53M |
| June 30, 2017 | 16.48M |
| March 31, 2017 | 11.32M |
| December 31, 2016 | 7.512M |
| September 30, 2016 | 4.062M |
| June 30, 2016 | 1.35M |
| March 31, 2016 | 1.21M |
| December 31, 2015 | 1.003M |
| September 30, 2015 | 0.6917M |
| June 30, 2015 | 0.5149M |
| March 31, 2015 | 0.3299M |
| December 31, 2014 | 0.2481M |
| September 30, 2014 | 0.1135M |
| June 30, 2014 | 0.0411M |
| December 31, 2013 | 0.1491M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.907B |
| TG Therapeutics, Inc. | 225.80M |
| Travere Therapeutics, Inc. | 227.14M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |